Tricyclic anti-depressants (TCAs), selective serotonin receptor inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase B (MAO B) inhibitors are some of the most commonly investigated groups of drugs for depression in PD patients. This evidence concerns the gene MAOB and depressive symptom measurement.